{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:24:31Z","timestamp":1793118271516,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.ygyno.2014.03.576","type":"journal-article","created":{"date-parts":[[2014,4,5]],"date-time":"2014-04-05T18:31:20Z","timestamp":1396722680000},"page":"427-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5)"],"prefix":"10.1016","volume":"133","author":[{"given":"G\u00fcnter","family":"Emons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigor","family":"Gorchev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Wimberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"St\u00e4hle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Hanker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Hilpert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Sindermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Gr\u00fcndker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2014.03.576_bb0130","series-title":"American Cancer Society: Cancer Facts and Figs. 2013","year":"2013"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0135","author":"ECO, European Cancer Observatory"},{"issue":"7","key":"10.1016\/j.ygyno.2014.03.576_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010482","article-title":"Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer","author":"Lawrie","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0020","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.2011.38.8082","article-title":"Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer","volume":"30","author":"Colombo","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0025","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0030","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0035","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2009.27.8911","article-title":"Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group","volume":"29","author":"Sehouli","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0304-3835(98)00316-4","article-title":"Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers","volume":"136","author":"Halmos","year":"1999","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0045","first-page":"3742","article-title":"Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers","volume":"9","author":"Bajo","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0050","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1043-2760(97)00155-0","article-title":"Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells","volume":"8","author":"Emons","year":"1997","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0055","first-page":"1063","article-title":"Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines","volume":"17","author":"Westphalen","year":"2000","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000225410","article-title":"Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152","volume":"90","author":"Emons","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0065","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1067\/mob.2002.124278","article-title":"Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice","volume":"187","author":"Grundker","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0070","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2010.08.003","article-title":"Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors","volume":"119","author":"Emons","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0075","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0140","author":"Gynecologic Cancer Intergroup"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0085","first-page":"1481","article-title":"Targeted chemotherapy for triple-negative breast cancers via LHRH receptor","volume":"25","author":"Fost","year":"2011","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0090","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA-125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0095","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/(SICI)1097-0258(19981030)17:20<2301::AID-SIM927>3.0.CO;2-X","article-title":"Optimal flexible designs in phase II clinical trials","volume":"17","author":"Chen","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0100","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0889-8588(05)70158-1","article-title":"Hormonal interactions in ovarian cancer","volume":"13","author":"Emons","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0110","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0090-8258(03)00408-6","article-title":"Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer","volume":"90","author":"Verschraegen","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0115","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2013.07.080","article-title":"Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer","volume":"131","author":"Walters","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.576_bb0120","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1093\/annonc\/mds172","article-title":"Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer","volume":"23","author":"Verschraegen","year":"2012","journal-title":"Ann Oncol"},{"issue":"Suppl. 18","key":"10.1016\/j.ygyno.2014.03.576_bb0125","article-title":"AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)","volume":"30","author":"Pujade-Lauraine","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581400818X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581400818X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T08:32:33Z","timestamp":1565339553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581400818X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S009082581400818X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.03.576","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.03.576","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}